NRG/RTOG 1122: A phase 2, double‐blinded, placebo‐controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

NRG/RTOG 1122: A phase 2, double‐blinded, placebo‐controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma

Published:2020-03-10 Issue:12 Volume:126 Page:2821-2828
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Lee Eudocia Q.¹^ORCID,Zhang Peixin²,Wen Patrick Y.¹,Gerstner Elizabeth R.³,Reardon David A.¹^ORCID,Aldape Kenneth D.⁴,deGroot John F.⁵,Pan Edward⁶^ORCID,Raizer Jeffrey J.⁷,Kim Lyndon J.⁸,Chmura Steven J.⁹,Robins H. Ian¹⁰,Connelly Jennifer M.¹¹,Battiste James D.¹²,Villano John L.¹³^ORCID,Wagle Naveed¹⁴,Merrell Ryan T.¹⁵,Wendland Merideth M.¹⁶,Mehta Minesh P.¹⁷

Affiliation:

1. Dana‐Farber/Brigham and Women's Cancer Center Boston Massachusetts

2. NRG Oncology Statistics and Data Management Center American College of Radiology Philadelphia Pennsylvania

3. Massachusetts General Hospital Boston Massachusetts

4. Toronto General Hospital Toronto Ontario Canada

5. The University of Texas MD Anderson Cancer Center Houston Texas

6. University of Texas Southwestern Medical Center Dallas Texas

7. Northwestern University Evanston Illinois

8. Thomas Jefferson University Hospital Philadelphia Pennsylvania

9. University of Chicago Comprehensive Cancer Center Chicago Illinois

10. University of Wisconsin Hospital and Clinics Madison Wisconsin

11. Froedtert and the Medical College of Wisconsin Milwaukee Wisconsin

12. University of Oklahoma Health Sciences Center Oklahoma City Oklahoma

13. University of Kentucky Lexington Kentucky

14. University of Southern California Los Angeles California

15. North Shore University Health System Evanston Illinois

16. The US Oncology Network‐Willamette Valley Cancer Institute Eugene Oregon

17. Baptist Hospital of Miami Miami Florida

Funder

National Cancer Institute

Amgen

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32811

Reference30 articles.

1. Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

2. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

3. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio

4. A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

5. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effects of the combination therapy of chemotherapy drugs on the fluctuations of genes involved in the TLR signaling pathway in glioblastoma multiforme therapy;Biomedicine & Pharmacotherapy;2024-08

2. Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review;Expert Review of Anticancer Therapy;2024-07-08

3. NDC80/HEC1 promotes macrophage polarization and predicts glioma prognosis via single‐cell RNA‐seq and in vitro experiment;CNS Neuroscience & Therapeutics;2024-07

4. Targeted agents in patients with progressive glioblastoma—A systematic meta‐analysis of randomized clinical trials;Cancer Medicine;2024-06

5. Crosstalk between glioblastoma and tumor microenvironment drives proneural–mesenchymal transition through ligand-receptor interactions;Genes & Diseases;2024-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3